SMSPHARMA

Q2FY26 Quarterly Result Announced for SMS Pharmaceuticals Ltd.

Q2FY26 Quarterly Result Announced for SMS Pharmaceuticals Ltd. -

Pharmaceuticals company SMS Pharmaceuticals announced Q2FY26 results Revenue grew 23% YoY driven by higher volumes and market share gains Gross margin expanded 30% YoY, driven by backward integration EBITDA increased 54% YoY, aided by operating leverage PAT stood at Rs 25.32 crore, up by 80% YoY; Record highest in a quarter Operating cash flows remained strong, supporting ongoing capex Rs 280 crore Capex programme on track for completion by November 2026 On track to achieve our FY26 outlook P. Vamsi Krishna, Executive Director, stated: "We concluded Q2FY26 on a strong note with 80% PAT growth YoY. We continued to see strong demand across our diversified portfolio, with market share gains in key APIs driving revenue growth. This quarter marks an inflection point as our backward integration efforts are now driving margin expansion. This has strengthened our value proposition to existing customers and is helping us expand our customer base in regulated markets. all this is for information. This is not a buy/sell recommendation. thank you, Technofunda24